Healthcare Investors Dedicated to Partnering with Exceptional Companies

Our mission is to unite our industry expertise and capital with entrepreneurs and management teams to deliver successful results and improve the lives of patients.

AVEGO’S HISTORY

From Operating to Investing


Avego was founded in 2015 by healthcare industry veterans with a passion for building high-growth, market-leading companies. Prior to forming Avego, our founders built and led several successful pharmaceutical companies, all of which culminated with strategic trade sales that generated significant value for their shareholders and management teams.

Our multi-pronged approach to investing allows us to partner with healthcare companies at various stages and provides us significant flexibility in structuring investments. Across all that we do, we are committed to advancing the healthcare industry and benefitting its stakeholders.

Our foundational strategy, Avego Healthcare Capital, has resulted in the creation and expansion of multiple companies, including several with international operations, that are developing and commercializing important therapeutics, medical products, and services for patients, physicians, and other customers in the U.S. and around the world. In 2019 and 2020, we completed the IPO of our SPAC, Amplitude Healthcare Acquisition Corporation, and launched Avego BioScience Capital. Through these two strategies, we are partnering with leading life sciences companies to drive critical progress toward the successful development of new products and services. Also established in 2020, Velan Capital pursues a high conviction long/short public equity strategy focused exclusively on the healthcare sector, with the goal of producing superior risk-adjusted returns.

AVEGO’S TEAM

Experienced. Collaborative.
Trusted Partners.

Investment Team

Bala Venkataraman

Founder and Managing Partner

Read more

Thomas Vandervort

Managing Partner

Read more

James Flexner

Managing Partner

Read more

Adam Morgan

Partner and CIO of Velan Capital

Read more

Vishal Kapoor

Partner

Read more

Kevin McNeill

Principal

Read more

David DeMartino

Senior Analyst, Velan Capital

Read more

Jerry Liao

Vice President

Read more

Jordan McLean

Vice President

Read more

Minh Vong, PhD

Senior Associate

Read more

Smit Savani

Associate

Read more

Finance and Operations

Jim Zenker

Chief Financial Officer

Read more

Operating Partners

Virinder Nohria, MD, PhD

Read more

Senior Advisors

John Devane, PhD

Read more

Bala Venkataraman

Founder and Managing Partner

Mr. Venkataraman is the Founder of Avego and an experienced operating executive from the pharmaceutical industry. He was also CEO of Amplitude Healthcare Acquisition Corporation, a life sciences focused special purpose acquisition company, until its merger with Jasper Therapeutics in September 2021. Since 2003, Mr. Venkataraman has launched, financially sponsored, and successfully built six pharmaceutical companies. Previously, Mr. Venkataraman was Co-Founder and Executive Chairman of Vidara Therapeutics until its sale to Horizon Pharma in September 2014. Prior to founding Vidara Therapeutics, Mr. Venkataraman was the Co-Founder and CEO of Alaven Pharmaceutical from 2003 until its sale to Meda Pharma in October 2010. Mr. Venkataraman also served as COO, CFO, and VP of Business Development, Strategic Planning and Operations at First Horizon Pharmaceutical (now Shionogi Pharma). Mr. Venkataraman holds an MS in Chemistry from Case Western University and an MBA from the Wharton School of the University of Pennsylvania.

Thomas Vandervort

Managing Partner

Mr. Vandervort joined Avego in 2015.  His background ranges across numerous positions in the pharmaceutical and pharmaceutical services industries, including the 3PL DDN Pharmaceutical Logistics and the ultra-orphan drug specialty pharmacy Centric Health Resources, as well as leadership roles in business development for West-Ward Pharmaceuticals and IGI Laboratories (now Teligent, Inc.).  As a sales leader for DDN and Centric, Mr. Vandervort built a brand for each company as the service provider of choice, as evidenced by the rapid growth in new clients and profitability for both companies.  Mr. Vandervort led M&A for West-Ward and was part of the team that acquired Baxter’s multi-source injectable business as well as numerous products that expanded West-Ward’s R&D portfolio to include NDAs as well as paragraph IV challenges. With IGI laboratories, Mr. Vandervort led multiple M&A transactions, including deals with Valeant and Concordia, as well as the acquisition of the Canadian generic injectable company, Alveda Pharma, Inc.  Mr. Vandervort has a BA from Bethany College in Bethany, WV and an MA from Duquesne University in Pittsburgh, PA.

James Flexner

Managing Partner

Mr. Flexner joined Avego in 2017. Previously, he was an investment professional with Metalmark Capital, where he focused on leveraged buyout transactions and growth equity investments in healthcare companies. Mr. Flexner began his career as an investment banker in the Global Healthcare Group at Morgan Stanley, where he executed multiple transactions across the life sciences and healthcare services industries. Mr. Flexner graduated from Dartmouth College with a BA degree in Economics and Chemistry.

Adam Morgan

Partner and CIO of Velan Capital

Mr. Morgan has a career spanning nearly two decades through both the healthcare industry as well as fundamental asset management.  From 2018 to 2020, he was a Senior Analyst at healthcare dedicated Broadfin Capital covering the Biotechnology and Pharmaceutical sectors. Prior to Broadfin Capital, Mr. Morgan was a Senior Analyst covering Medical Devices and Specialty Pharmaceuticals at Iguana Healthcare from 2015-2017, and from 2014-2015 he was an Analyst at Pura Vida Investments, where he covered global Medical Devices.  Mr. Morgan transitioned from the healthcare industry through a sell-side role as a Research Associate at Cowen and Company on the firm’s Medical Supplies & Devices team that bolstered his financial acumen against a strong fundamental understanding of the industry. He also spent over a decade at various medical device companies in expanding leadership roles ranging from engineering to sales and marketing to strategy and brings a deep operational understanding of the sector. Mr. Morgan received his BS in Chemistry from the University of Minnesota and his MBA from the Carlson School of Management at the University of Minnesota. ​

Vishal Kapoor

Partner

Mr. Kapoor joined Avego in 2021. He was also President of Amplitude Healthcare Acquisition Corporation, a life sciences focused special purpose acquisition company, until its merger with Jasper Therapeutics in September 2021. Previously, Mr. Kapoor was Chief Business Officer of Iveric bio (formerly known as Ophthotech). At Iveric, he was responsible for acquiring an industry-leading portfolio of gene therapy and therapeutic assets in ophthalmology. Prior to Iveric, Mr. Kapoor was responsible for business development and portfolio strategy in his role as Director of Corporate Development at NPS Pharma, which was acquired by Shire in 2015 for $5.2 billion. Prior to NPS, Mr. Kapoor spent 9 years at Genentech in a variety of positions, including leading strategy for ophthalmology and CNS pipeline assets, Lucentis marketing, commercial assessments for business development and medical affairs. In addition, Mr. Kapoor has previously worked at Pfizer. Mr. Kapoor holds an MBA in Finance and Management from Columbia Business School and a BA in Biology from Columbia University.

Kevin McNeill

Principal

Mr. McNeill joined Avego in 2018. Previously, he was a Vice President at Leerink Partners, a healthcare-only investment bank. Mr. McNeill began his career at Lazard where he also advised middle-market healthcare companies. During his investment banking career, Mr. McNeill executed over 15 strategic transactions for companies in the pharmaceutical and life sciences sectors. Mr. McNeill graduated from the Kenan-Flagler Business School at the University of North Carolina at Chapel Hill with a BS degree in Business Administration.

David DeMartino

Senior Analyst, Velan Capital

Mr. DeMartino joined Velan Capital in 2020. His career has encompassed over two decades in healthcare asset management, equity research and investment banking. Previously, Mr. DeMartino was an Analyst at Citadel, where he managed a Biotechnology portfolio. Prior to Citadel, Mr. DeMartino was a Senior Analyst at Pura Vida Investments, covering the Biotechnology, Medical Devices and Healthcare Technology industries. In addition to investing in publicly traded companies at Pura Vida, Mr. DeMartino worked on private company investments. Prior to joining Pura Vida, Mr. DeMartino was a Portfolio Manager at DnB Asset Management covering the overall healthcare industry. Prior to DnB, Mr. DeMartino spent several years in sellside equity research, initially covering healthcare facilities at Deutsche Bank and then Medical Devices at Credit Suisse. Mr. DeMartino started his career in healthcare investment banking at Deutsche Bank. Mr. DeMartino received his B.A in Economics from Washington and Lee University.

Jerry Liao

Vice President

Mr. Liao joined Avego in 2021. Previously, he was a Vice President at Signet Healthcare Partners, where he focused on growth equity and venture investments in pharmaceutical products (branded and generics), pharmaceutical services, and medical device companies. Mr. Liao’s notable investment experience includes Vigene Biosciences, Goodwin Biotechnology, and Leading Pharma. Mr. Liao began his career as an investment banker in the healthcare groups at Nomura and Jefferies after graduating from The Pennsylvania State University, Smeal College of Business with an MS degree in Accounting and a BS degree in Finance, Accounting, and Economics.

Jordan McLean

Vice President

Mr. McLean joined Avego in 2017. Previously, he was an investment banker at Leerink Partners, where he focused on M&A advisory across specialty brand and generic pharmaceutical sectors. Mr. McLean’s notable transaction experience includes Edenbridge Pharmaceuticals’ sale to Tailwind Capital, the sale of Raptor Pharmaceutical Corp. to Horizon Pharma, and the successful defense of Depomed against Horizon Pharma’s attempted hostile takeover. Mr. McLean began his career in the Healthcare Group at Lazard Middle Market after graduating from Franklin & Marshall College with a BA in Business, Organizations & Society.

Minh Vong, PhD

Senior Associate

Dr. Vong joined Avego in 2021. Previously, he was an equity research analyst covering Biotechnology at Truist Securities. Prior to Truist Securities, Dr. Vong covered Biotechnology at Beacon VP Capital. Dr. Vong is a published scientist, having studied different aspects of virology over eight years. Dr. Vong received his PhD in Biochemistry from Harvard University and his BS in Biology from The University of the Sciences in Philadelphia.

Smit Savani

Associate

Mr. Savani joined Avego in 2020. Previously, he was an investment banker at Piper Sandler, where he executed multiple transactions in the life science tools & diagnostics and healthcare services sectors. Mr. Savani holds an BS in Business Administration from North Carolina State University and an MS in Finance from Vanderbilt’s Owen Graduate School of Management.

Jim Zenker

Chief Financial Officer

Mr. Zenker joined Avego in 2021. Previously, he was a Senior Controller with Deerfield Management Company where he gained experience working with the Accounting, Finance, Operations, Legal, Compliance and Investor Relations teams. Prior to joining Deerfield, Mr. Zenker was an Analyst at ESL Investments, Inc. working on the Finance and Operations team. Mr. Zenker started his career at Ernst & Young LLP as a Financial Consultant. Mr. Zenker graduated from the University of Notre Dame with a Bachelor of Business Administration degree in Finance and a Master of Science in Accountancy degree.

Virinder Nohria, MD, PhD

Dr. Nohria currently serves as Chairman of the Board for Saol Therapeutics and Sebela Pharmaceuticals. He is an experienced biotechnology entrepreneur and drug developer with a track record of success in the pharmaceutical and biotechnology sector. Dr. Nohria is a board-certified neurologist with special qualification in child neurology. Dr. Nohria co-founded Vidara Therapeutics in 2011 and served as its President and Chief Medical Officer until the company’s sale to Horizon Therapeutics in 2014. In the past, Dr. Nohria was part of the founding team of Alaven Pharmaceutical and Alaven Consumer Health LLC and served as its Chief Medical Officer, Chief Compliance Officer and Executive Vice President from 2008 until its sale to Meda Pharma in 2010. Additionally, Dr. Nohria worked for Eli Lilly on Zyprexa and at UCB, where he was clinical lead for submission and commercialization of Keppra in the United States. Between 2003 and 2005, he was Vice President and Chief Medical Officer of Xcel Pharmaceuticals where he led development of retigabine (ezogabine) for the treatment of epilepsy. Dr. Nohria’s medical training was conducted at the University of Cambridge in England. His postgraduate training was completed in the United Kingdom and the United States at Duke University. He also holds a Ph.D. in Neuropharmacology and has authored many publications and book chapters.

John Devane, PhD

Dr. Devane currently serves as a board member to Saol Therapeutics and Sebela Pharmaceuticals. Most recently, Dr. Devane was Chief Scientific Officer (CSO) with Horizon Pharma Ireland Ltd. and previously (2012-2014) served as CSO to Vidara Therapeutics Research Ltd. In the past, Dr. Devane was part of the founding team of AGI Therapeutics plc. and served as its CEO from 2004-2012. Additionally, Dr. Devane founded and led Athpharma Ltd. as CEO from 2002-2005. Dr. Devane worked for Elan Corporation from 1981 to 2001 and held various senior leadership positions, including Executive Vice President R&D (1993-2001) and Senior Vice President Clinical & Regulatory, where he led key clinical trial programs in the USA and negotiated NDA approvals directly with FDA. During the period 1990 to 2001, Dr. Devane and his team were responsible for 6 NDA and 3 ANDA approvals. Dr. Devane has had a long career designing and successfully delivering major product development programs spanning activities in preclinical, clinical, manufacturing, regulatory, and intellectual property. He has a deep knowledge in pharmacology, drug delivery, clinical development, regulatory affairs and intellectual property. Dr. Devane is the inventor/co-inventor on many granted and pending patent applications and has also been widely published in scientific/medical literature. His graduate and post-graduate scientific training was conducted at University College in Dublin, Ireland. He received a diploma in Accounting & Finance (ACCA) by exam and received a certificate and diploma from the Institute of Directors (UK) by exam relating to their Chartered Director Program.